Share Price and Basic Stock Data
Last Updated: December 16, 2025, 7:44 am
| PEG Ratio | -311.63 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gujarat Alkalies & Chemicals Ltd (GACL) operates in the chemicals sector, primarily focusing on inorganic chemicals like caustic soda and soda ash. As of the latest reporting, the company’s share price stood at ₹506, with a market capitalization of ₹3,716 Cr. The revenue trajectory has shown fluctuations; for instance, GACL reported sales of ₹4,516 Cr for FY 2023, a notable rise from ₹3,759 Cr in FY 2022. However, the trailing twelve months (TTM) sales dipped slightly to ₹4,201 Cr, indicating some volatility in revenue streams. The quarterly sales figures reveal a similar trend, with the most recent quarter (Sep 2023) recording sales of ₹971 Cr, down from ₹1,138 Cr in Mar 2023. This inconsistency raises questions about the underlying demand for their products and the impact of market conditions on their performance.
Profitability and Efficiency Metrics
Profitability has been a significant concern for GACL, particularly in recent quarters. The operating profit margin (OPM) has seen a dramatic decline, falling to just 3% in Jun 2023 from a high of 31% in Jun 2022. This deterioration is reflected in the net profit, which reported a loss of ₹34 Cr for TTM, a stark contrast to the profit of ₹410 Cr in FY 2023. The interest coverage ratio (ICR) remains relatively strong at 8.95x, suggesting that GACL can comfortably meet its interest obligations. However, the return on equity (ROE) is a meager 1.13%, indicating inefficiency in generating returns for shareholders. The decline in profitability metrics raises concerns about the sustainability of its operations, especially in a competitive market.
Balance Sheet Strength and Financial Ratios
GACL’s balance sheet reflects a mixed picture. The company’s borrowings have increased to ₹637 Cr, yet it maintains a low debt-to-equity ratio of 0.09, which indicates a conservative approach to leverage. This is complemented by reserves of ₹5,497 Cr, showcasing a solid buffer against market volatility. The price-to-book value ratio stands at 0.75x, suggesting that the stock may be undervalued compared to its net assets. However, the company’s current ratio has dipped to 1.13x, which is still above the benchmark of 1, but highlights a tightening liquidity position. The cash conversion cycle stands at 19 days, which is efficient, yet the declining operating profit raises concerns about its ability to convert sales into cash effectively.
Shareholding Pattern and Investor Confidence
Investor sentiment appears cautious, as reflected in GACL’s shareholding pattern. Promoters hold a consistent 46.28% stake, which can instill confidence among retail investors. However, the foreign institutional investors (FIIs) have reduced their stake from 2.07% in Dec 2022 to just 1.02% by Jun 2025, signaling some withdrawal of international investor confidence. Domestic institutional investors (DIIs) have gradually increased their holdings from 1.45% to 4.52%, which may indicate a more favorable outlook among local investors. The number of shareholders has also decreased from 85,354 in Dec 2022 to 70,371 in Sep 2025, suggesting that some investors may be exiting the stock amidst declining profitability and market uncertainties.
Outlook, Risks, and Final Insight
Looking ahead, GACL faces several challenges and opportunities. The volatility in revenue and profitability metrics poses a significant risk, as ongoing operational inefficiencies could lead to further losses. Additionally, the declining interest from FIIs may affect the stock’s liquidity and investor sentiment. On the other hand, the company’s strong balance sheet and low leverage provide a cushion against economic downturns. Investors might consider the potential for recovery if GACL can streamline its operations and improve its profit margins. However, they should remain cautious about the cyclical nature of the chemicals market and the impact of global economic conditions. Overall, while GACL has strengths in its financial stability, the risks associated with declining profitability and investor confidence warrant careful consideration before making investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 26.1 Cr. | 56.8 | 69.0/37.5 | 2,613 | 11.6 | 0.00 % | 0.48 % | 13.7 % | 10.0 |
| Standard Industries Ltd | 104 Cr. | 16.2 | 29.9/15.4 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 3,776 Cr. | 514 | 779/484 | 25,173 | 759 | 3.07 % | 0.34 % | 1.13 % | 10.0 |
| GHCL Ltd | 5,291 Cr. | 576 | 779/511 | 9.29 | 378 | 2.09 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 19,512 Cr. | 766 | 1,107/747 | 59.9 | 877 | 1.44 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 5,870.00 Cr | 398.83 | 5,579.98 | 389.00 | 1.15% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,128 | 1,127 | 1,123 | 1,138 | 913 | 971 | 921 | 1,002 | 977 | 991 | 1,029 | 1,075 | 1,105 |
| Expenses | 778 | 969 | 885 | 936 | 882 | 955 | 941 | 998 | 923 | 945 | 951 | 974 | 1,010 |
| Operating Profit | 351 | 159 | 238 | 202 | 31 | 16 | -20 | 4 | 54 | 46 | 78 | 101 | 95 |
| OPM % | 31% | 14% | 21% | 18% | 3% | 2% | -2% | 0% | 6% | 5% | 8% | 9% | 9% |
| Other Income | 6 | 22 | 6 | 8 | 12 | 71 | 5 | 3 | 3 | 49 | 15 | 24 | 8 |
| Interest | 2 | 3 | 8 | 8 | 10 | 11 | 11 | 12 | 11 | 11 | 10 | 18 | 14 |
| Depreciation | 50 | 60 | 79 | 88 | 89 | 95 | 96 | 97 | 97 | 100 | 98 | 97 | 102 |
| Profit before tax | 305 | 118 | 157 | 115 | -57 | -18 | -123 | -102 | -50 | -16 | -15 | 10 | -12 |
| Tax % | 37% | 49% | 44% | 38% | 0% | -0% | -6% | -55% | -11% | 15% | -27% | 13% | 15% |
| Net Profit | 191 | 61 | 87 | 71 | -57 | -18 | -115 | -46 | -45 | -18 | -11 | 9 | -14 |
| EPS in Rs | 25.99 | 8.24 | 11.87 | 9.67 | -7.78 | -2.50 | -15.68 | -6.29 | -6.06 | -2.48 | -1.53 | 1.20 | -1.88 |
Last Updated: August 20, 2025, 10:00 am
Below is a detailed analysis of the quarterly data for Gujarat Alkalies & Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,105.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,075.00 Cr. (Mar 2025) to 1,105.00 Cr., marking an increase of 30.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,010.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 974.00 Cr. (Mar 2025) to 1,010.00 Cr., marking an increase of 36.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Jun 2025, the value is 9.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00%.
- For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 16.00 Cr..
- For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 102.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 97.00 Cr. (Mar 2025) to 102.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 10.00 Cr. (Mar 2025) to -12.00 Cr., marking a decrease of 22.00 Cr..
- For Tax %, as of Jun 2025, the value is 15.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 15.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 23.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.88. The value appears to be declining and may need further review. It has decreased from 1.20 (Mar 2025) to -1.88, marking a decrease of 3.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:17 am
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,995 | 2,070 | 2,455 | 3,161 | 2,725 | 2,429 | 3,759 | 4,516 | 3,807 | 4,073 | 4,293 |
| Expenses | 1,660 | 1,622 | 1,669 | 2,046 | 2,148 | 2,072 | 2,774 | 3,568 | 3,775 | 3,793 | 3,945 |
| Operating Profit | 335 | 448 | 786 | 1,115 | 577 | 357 | 984 | 949 | 32 | 279 | 348 |
| OPM % | 17% | 22% | 32% | 35% | 21% | 15% | 26% | 21% | 1% | 7% | 8% |
| Other Income | 45 | 56 | 106 | 62 | 90 | 67 | 46 | 42 | 90 | 92 | 107 |
| Interest | 10 | 13 | 15 | 21 | 14 | 15 | 6 | 19 | 45 | 51 | 58 |
| Depreciation | 107 | 111 | 127 | 140 | 162 | 174 | 198 | 276 | 377 | 392 | 401 |
| Profit before tax | 262 | 381 | 749 | 1,016 | 491 | 235 | 826 | 695 | -300 | -71 | -4 |
| Tax % | 16% | 19% | 29% | 32% | 32% | 29% | 32% | 41% | -21% | -9% | |
| Net Profit | 220 | 307 | 534 | 690 | 332 | 166 | 560 | 410 | -237 | -65 | 0 |
| EPS in Rs | 29.90 | 41.85 | 72.78 | 93.98 | 45.22 | 22.57 | 76.22 | 55.78 | -32.25 | -8.87 | 0.02 |
| Dividend Payout % | 15% | 12% | 9% | 9% | 18% | 35% | 13% | 42% | -43% | -178% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 39.55% | 73.94% | 29.21% | -51.88% | -50.00% | 237.35% | -26.79% | -157.80% | 72.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 34.40% | -44.73% | -81.10% | 1.88% | 287.35% | -264.14% | -131.02% | 230.38% |
Gujarat Alkalies & Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 3% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 85% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | -15% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 1% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 5:30 am
Balance Sheet
Last Updated: December 4, 2025, 1:19 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 |
| Reserves | 2,854 | 3,282 | 3,748 | 4,222 | 4,522 | 5,301 | 5,826 | 6,066 | 6,002 | 5,596 | 5,497 |
| Borrowings | 295 | 353 | 291 | 247 | 205 | 498 | 594 | 597 | 544 | 561 | 637 |
| Other Liabilities | 671 | 726 | 859 | 988 | 1,090 | 1,282 | 1,484 | 1,599 | 1,404 | 1,756 | 2,002 |
| Total Liabilities | 3,894 | 4,435 | 4,970 | 5,531 | 5,891 | 7,154 | 7,977 | 8,335 | 8,023 | 7,987 | 8,209 |
| Fixed Assets | 1,821 | 2,073 | 2,104 | 2,300 | 2,610 | 2,587 | 2,702 | 4,250 | 4,617 | 4,584 | 4,522 |
| CWIP | 83 | 151 | 252 | 307 | 445 | 1,109 | 1,787 | 544 | 95 | 79 | 37 |
| Investments | 854 | 1,016 | 1,145 | 1,065 | 1,242 | 2,092 | 2,110 | 1,831 | 2,093 | 1,976 | 2,044 |
| Other Assets | 1,136 | 1,196 | 1,469 | 1,858 | 1,594 | 1,366 | 1,379 | 1,710 | 1,218 | 1,348 | 1,607 |
| Total Assets | 3,894 | 4,435 | 4,970 | 5,531 | 5,891 | 7,154 | 7,977 | 8,335 | 8,023 | 7,987 | 8,209 |
Below is a detailed analysis of the balance sheet data for Gujarat Alkalies & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 73.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 73.00 Cr..
- For Reserves, as of Sep 2025, the value is 5,497.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,596.00 Cr. (Mar 2025) to 5,497.00 Cr., marking a decrease of 99.00 Cr..
- For Borrowings, as of Sep 2025, the value is 637.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 561.00 Cr. (Mar 2025) to 637.00 Cr., marking an increase of 76.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,002.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,756.00 Cr. (Mar 2025) to 2,002.00 Cr., marking an increase of 246.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8,209.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,987.00 Cr. (Mar 2025) to 8,209.00 Cr., marking an increase of 222.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,522.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,584.00 Cr. (Mar 2025) to 4,522.00 Cr., marking a decrease of 62.00 Cr..
- For CWIP, as of Sep 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 79.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 42.00 Cr..
- For Investments, as of Sep 2025, the value is 2,044.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,976.00 Cr. (Mar 2025) to 2,044.00 Cr., marking an increase of 68.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,607.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,348.00 Cr. (Mar 2025) to 1,607.00 Cr., marking an increase of 259.00 Cr..
- For Total Assets, as of Sep 2025, the value is 8,209.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,987.00 Cr. (Mar 2025) to 8,209.00 Cr., marking an increase of 222.00 Cr..
Notably, the Reserves (5,497.00 Cr.) exceed the Borrowings (637.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 40.00 | 95.00 | 495.00 | -246.00 | 372.00 | -141.00 | 390.00 | 352.00 | -512.00 | -282.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 58 | 60 | 56 | 50 | 43 | 29 | 23 | 17 | 24 |
| Inventory Days | 99 | 94 | 147 | 99 | 92 | 88 | 101 | 111 | 93 | 110 |
| Days Payable | 99 | 125 | 154 | 134 | 126 | 111 | 101 | 119 | 86 | 115 |
| Cash Conversion Cycle | 60 | 27 | 53 | 22 | 17 | 21 | 29 | 15 | 25 | 19 |
| Working Capital Days | 89 | 81 | 98 | 96 | 107 | 10 | 4 | 5 | -1 | -3 |
| ROCE % | 11% | 18% | 24% | 11% | 5% | 13% | 11% | -4% | -0% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Smallcap Fund | 1,746,809 | 1.1 | 92.67 | 1,745,000 | 2025-12-15 00:33:14 | 0.1% |
| ICICI Prudential PSU Equity Fund | 312,307 | 0.86 | 16.57 | N/A | N/A | N/A |
| ICICI Prudential Childrens Fund | 100,338 | 0.37 | 5.32 | N/A | N/A | N/A |
| ICICI Prudential Manufacturing Fund | 94,975 | 0.08 | 5.04 | N/A | N/A | N/A |
| ICICI Prudential Regular Savings Fund | 70,257 | 0.11 | 3.73 | 75,047 | 2025-12-07 09:28:07 | -6.38% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -8.87 | -32.25 | 55.78 | 76.22 | 22.57 |
| Diluted EPS (Rs.) | -8.87 | -32.25 | 55.78 | 76.22 | 22.57 |
| Cash EPS (Rs.) | 55.57 | 33.38 | 115.99 | 103.46 | 46.46 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 772.02 | 827.30 | 835.97 | 803.30 | 731.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 772.02 | 827.30 | 835.97 | 803.30 | 731.86 |
| Revenue From Operations / Share (Rs.) | 554.60 | 518.34 | 615.01 | 511.82 | 330.82 |
| PBDIT / Share (Rs.) | 61.62 | 30.79 | 157.51 | 140.60 | 57.96 |
| PBIT / Share (Rs.) | 8.21 | -20.60 | 119.92 | 113.67 | 34.21 |
| PBT / Share (Rs.) | 1.32 | -26.67 | 117.27 | 112.83 | 32.11 |
| Net Profit / Share (Rs.) | 2.15 | -18.01 | 78.39 | 76.52 | 22.72 |
| NP After MI And SOA / Share (Rs.) | -8.87 | -32.25 | 55.78 | 76.22 | 22.57 |
| PBDIT Margin (%) | 11.11 | 5.93 | 25.61 | 27.47 | 17.51 |
| PBIT Margin (%) | 1.47 | -3.97 | 19.49 | 22.20 | 10.34 |
| PBT Margin (%) | 0.23 | -5.14 | 19.06 | 22.04 | 9.70 |
| Net Profit Margin (%) | 0.38 | -3.47 | 12.74 | 14.95 | 6.86 |
| NP After MI And SOA Margin (%) | -1.59 | -6.22 | 9.06 | 14.89 | 6.82 |
| Return on Networth / Equity (%) | -1.14 | -3.89 | 6.67 | 9.48 | 3.08 |
| Return on Capital Employeed (%) | 0.85 | -2.07 | 11.75 | 11.52 | 3.84 |
| Return On Assets (%) | -0.81 | -2.95 | 4.91 | 7.01 | 2.31 |
| Long Term Debt / Equity (X) | 0.05 | 0.05 | 0.07 | 0.09 | 0.08 |
| Total Debt / Equity (X) | 0.09 | 0.08 | 0.09 | 0.10 | 0.08 |
| Asset Turnover Ratio (%) | 0.50 | 0.46 | 0.55 | 0.49 | 0.37 |
| Current Ratio (X) | 1.13 | 1.23 | 1.68 | 1.49 | 1.78 |
| Quick Ratio (X) | 0.60 | 0.67 | 1.13 | 1.01 | 1.41 |
| Inventory Turnover Ratio (X) | 9.12 | 6.75 | 6.45 | 6.97 | 6.16 |
| Dividend Payout Ratio (NP) (%) | -156.19 | -73.02 | 17.92 | 10.49 | 35.44 |
| Dividend Payout Ratio (CP) (%) | 31.08 | 123.03 | 10.70 | 7.75 | 17.27 |
| Earning Retention Ratio (%) | 256.19 | 173.02 | 82.08 | 89.51 | 64.56 |
| Cash Earning Retention Ratio (%) | 68.92 | -23.03 | 89.30 | 92.25 | 82.73 |
| Interest Coverage Ratio (X) | 8.95 | 5.07 | 59.43 | 168.00 | 27.53 |
| Interest Coverage Ratio (Post Tax) (X) | 1.31 | -1.97 | 30.58 | 92.43 | 11.79 |
| Enterprise Value (Cr.) | 4670.05 | 5324.43 | 4435.11 | 6873.06 | 2607.27 |
| EV / Net Operating Revenue (X) | 1.15 | 1.40 | 0.98 | 1.83 | 1.07 |
| EV / EBITDA (X) | 10.32 | 23.55 | 3.83 | 6.66 | 6.13 |
| MarketCap / Net Operating Revenue (X) | 1.04 | 1.30 | 0.95 | 1.75 | 1.04 |
| Retention Ratios (%) | 256.19 | 173.02 | 82.07 | 89.50 | 64.55 |
| Price / BV (X) | 0.75 | 0.81 | 0.70 | 1.12 | 0.47 |
| Price / Net Operating Revenue (X) | 1.04 | 1.30 | 0.95 | 1.75 | 1.04 |
| EarningsYield | -0.01 | -0.04 | 0.09 | 0.08 | 0.06 |
After reviewing the key financial ratios for Gujarat Alkalies & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 5. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 5. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
- For Cash EPS (Rs.), as of Mar 25, the value is 55.57. This value is within the healthy range. It has increased from 33.38 (Mar 24) to 55.57, marking an increase of 22.19.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 772.02. It has decreased from 827.30 (Mar 24) to 772.02, marking a decrease of 55.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 772.02. It has decreased from 827.30 (Mar 24) to 772.02, marking a decrease of 55.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 554.60. It has increased from 518.34 (Mar 24) to 554.60, marking an increase of 36.26.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.62. This value is within the healthy range. It has increased from 30.79 (Mar 24) to 61.62, marking an increase of 30.83.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.21. This value is within the healthy range. It has increased from -20.60 (Mar 24) to 8.21, marking an increase of 28.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.32. This value is within the healthy range. It has increased from -26.67 (Mar 24) to 1.32, marking an increase of 27.99.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from -18.01 (Mar 24) to 2.15, marking an increase of 20.16.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 2. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
- For PBDIT Margin (%), as of Mar 25, the value is 11.11. This value is within the healthy range. It has increased from 5.93 (Mar 24) to 11.11, marking an increase of 5.18.
- For PBIT Margin (%), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 10. It has increased from -3.97 (Mar 24) to 1.47, marking an increase of 5.44.
- For PBT Margin (%), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 10. It has increased from -5.14 (Mar 24) to 0.23, marking an increase of 5.37.
- For Net Profit Margin (%), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 5. It has increased from -3.47 (Mar 24) to 0.38, marking an increase of 3.85.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.59. This value is below the healthy minimum of 8. It has increased from -6.22 (Mar 24) to -1.59, marking an increase of 4.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.14. This value is below the healthy minimum of 15. It has increased from -3.89 (Mar 24) to -1.14, marking an increase of 2.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 10. It has increased from -2.07 (Mar 24) to 0.85, marking an increase of 2.92.
- For Return On Assets (%), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 5. It has increased from -2.95 (Mar 24) to -0.81, marking an increase of 2.14.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.09, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.50. It has increased from 0.46 (Mar 24) to 0.50, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 1.5. It has decreased from 1.23 (Mar 24) to 1.13, marking a decrease of 0.10.
- For Quick Ratio (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 0.67 (Mar 24) to 0.60, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.12. This value exceeds the healthy maximum of 8. It has increased from 6.75 (Mar 24) to 9.12, marking an increase of 2.37.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -156.19. This value is below the healthy minimum of 20. It has decreased from -73.02 (Mar 24) to -156.19, marking a decrease of 83.17.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 31.08. This value is within the healthy range. It has decreased from 123.03 (Mar 24) to 31.08, marking a decrease of 91.95.
- For Earning Retention Ratio (%), as of Mar 25, the value is 256.19. This value exceeds the healthy maximum of 70. It has increased from 173.02 (Mar 24) to 256.19, marking an increase of 83.17.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 68.92. This value is within the healthy range. It has increased from -23.03 (Mar 24) to 68.92, marking an increase of 91.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.95. This value is within the healthy range. It has increased from 5.07 (Mar 24) to 8.95, marking an increase of 3.88.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 3. It has increased from -1.97 (Mar 24) to 1.31, marking an increase of 3.28.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,670.05. It has decreased from 5,324.43 (Mar 24) to 4,670.05, marking a decrease of 654.38.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.15, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 10.32. This value is within the healthy range. It has decreased from 23.55 (Mar 24) to 10.32, marking a decrease of 13.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.30 (Mar 24) to 1.04, marking a decrease of 0.26.
- For Retention Ratios (%), as of Mar 25, the value is 256.19. This value exceeds the healthy maximum of 70. It has increased from 173.02 (Mar 24) to 256.19, marking an increase of 83.17.
- For Price / BV (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.81 (Mar 24) to 0.75, marking a decrease of 0.06.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.30 (Mar 24) to 1.04, marking a decrease of 0.26.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to -0.01, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Alkalies & Chemicals Ltd:
- Net Profit Margin: 0.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.85% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.14% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.31
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.6
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25 (Industry average Stock P/E: 4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | P.O.: Ranoli, Vadodra District Gujarat 391350 | investor_relations@gacl.co.in http://www.gacl.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Hasmukh Adhia | Chairman |
| Ms. Avantika Singh Aulakh | Managing Director |
| Mr. Rajiv Lochan Jain | Independent Director |
| Mr. Nitin Shukla | Independent Director |
| Mr. Shridevi Shukla | Independent Director |
| Mr. Bimal Julka | Independent Director |
| Dr. Chinmay Ghoroi | Independent Director |
| Mr. S J Haider | Director |
| Dr. T Natarajan | Director |
FAQ
What is the intrinsic value of Gujarat Alkalies & Chemicals Ltd?
Gujarat Alkalies & Chemicals Ltd's intrinsic value (as of 16 December 2025) is 178023.55 which is 34534.93% higher the current market price of 514.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3,776 Cr. market cap, FY2025-2026 high/low of 779/484, reserves of ₹5,497 Cr, and liabilities of 8,209 Cr.
What is the Market Cap of Gujarat Alkalies & Chemicals Ltd?
The Market Cap of Gujarat Alkalies & Chemicals Ltd is 3,776 Cr..
What is the current Stock Price of Gujarat Alkalies & Chemicals Ltd as on 16 December 2025?
The current stock price of Gujarat Alkalies & Chemicals Ltd as on 16 December 2025 is 514.
What is the High / Low of Gujarat Alkalies & Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gujarat Alkalies & Chemicals Ltd stocks is 779/484.
What is the Stock P/E of Gujarat Alkalies & Chemicals Ltd?
The Stock P/E of Gujarat Alkalies & Chemicals Ltd is 25,173.
What is the Book Value of Gujarat Alkalies & Chemicals Ltd?
The Book Value of Gujarat Alkalies & Chemicals Ltd is 759.
What is the Dividend Yield of Gujarat Alkalies & Chemicals Ltd?
The Dividend Yield of Gujarat Alkalies & Chemicals Ltd is 3.07 %.
What is the ROCE of Gujarat Alkalies & Chemicals Ltd?
The ROCE of Gujarat Alkalies & Chemicals Ltd is 0.34 %.
What is the ROE of Gujarat Alkalies & Chemicals Ltd?
The ROE of Gujarat Alkalies & Chemicals Ltd is 1.13 %.
What is the Face Value of Gujarat Alkalies & Chemicals Ltd?
The Face Value of Gujarat Alkalies & Chemicals Ltd is 10.0.